GLP-1 receptor agonists in NAFLD

被引：37

作者：

Petit, J. -M. ^{[1
,2
]}

Verges, B. ^{[1
,2
]}

机构：

[1] Univ Bourgogne, Ctr Rech, INSERM, LNC UMR1231, Dijon, France

[2] CHU Francois Mitterand, Serv Diabetol & Endocrinol, BP 77908, F-21079 Dijon, France

来源：

DIABETES & METABOLISM | 2017年 / 43卷

关键词：

Steatosis; GLP-1 receptor agonists; type; 2; diabetes; Non-alcoholic fatty liver disease; Fibrosis; GLUCAGON-LIKE PEPTIDE-1; FATTY LIVER-DISEASE; HEPATIC STEATOSIS; NONALCOHOLIC STEATOHEPATITIS; MAGNETIC-RESONANCE; WEIGHT-LOSS; EXENATIDE; LIRAGLUTIDE; OBESITY; ANALOG;

D O I：

10.1016/S1262-3636(17)30070-8

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Non-alcoholic fatty liver disease (NAFLD) is very common in patients with type 2 diabetes (T2D), with approximately two-thirds having a diagnosis of the disease. Currently, the only validated treatment for NAFLD is weight loss. A number of studies of animal models and human trials have evaluated the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on liver fat content and suggest that the treatment could represent a new alternative for NAFLD management. In this review, our focus is on the main studies regarding the effects of GLP-1RAs on NAFLD. Also, the mechanisms that might explain their beneficial effects on liver diseases are analyzed. (C) 2017 Elsevier Masson SAS. All rights reserved.

引用

页码：2S28 / 2S33

页数：6

共 43 条

[1] Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis [J].

Armstrong, Matthew J. ;

Hull, Diana ;

Guo, Kathy ;

Barton, Darren ;

Hazlehurst, Jonathan M. ;

Gathercole, Laura L. ;

Nasiri, Maryam ;

Yu, Jinglei ;

Gough, Stephen C. ;

Newsome, Philip N. ;

Tomlinson, Jeremy W. .

JOURNAL OF HEPATOLOGY, 2016, 64 (02) :399-408

[2] Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study [J].

Armstrong, Matthew James ;

Gaunt, Piers ;

Aithal, Guruprasad P. ;

Barton, Darren ;

Hull, Diana ;

Parker, Richard ;

Hazlehurst, Jonathan M. ;

Guo, Kathy ;

Abouda, George ;

Aldersley, Mark A. ;

Stocken, Deborah ;

Gough, Stephen C. ;

Tomlinson, Jeremy W. ;

Brown, Rachel M. ;

Huebscher, Stefan G. ;

Newsome, Philip N. .

LANCET, 2016, 387 (10019) :679-690

[3] Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase [J].

Ben-Shlomo, Shani ;

Zvibel, Isabel ;

Shnell, Mati ;

Shlomai, Amir ;

Chepurko, Elena ;

Halpern, Zamir ;

Barzilai, Nir ;

Oren, Ran ;

Fishman, Sigal .

JOURNAL OF HEPATOLOGY, 2011, 54 (06) :1214-1223

[4] Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials [J].

Buse, John B. ;

Klonoff, David C. ;

Nielsen, Loretta L. ;

Guan, Xuesong ;

Bowlus, Christopher L. ;

Holcombe, John H. ;

Maggs, David G. ;

Wintle, Matthew E. .

CLINICAL THERAPEUTICS, 2007, 29 (01) :139-153

[5]

Cariou B, 2015, DIABETES METAB, V41, pS28, DOI 10.1016/S1262-3636(16)30006-4

[6] Nonalcoholic fatty liver disease in type 2 diabetes mellitus [J].

Cusi, Kenneth .

CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2009, 16 (02) :141-149

[7] Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists [J].

Cuthbertson, Daniel J. ;

Irwin, Andrew ;

Gardner, Chris J. ;

Daousi, Christina ;

Purewal, Tej ;

Furlong, Niall ;

Goenka, Niru ;

Thomas, E. Louise ;

Adams, Valerie L. ;

Pushpakom, Sudeep P. ;

Pirmohamed, Munir ;

Kemp, Graham J. .

PLOS ONE, 2012, 7 (12)

[8] Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice [J].

Ding, XK ;

Saxena, NK ;

Lin, SB ;

Gupta, N ;

Anania, FA .

HEPATOLOGY, 2006, 43 (01) :173-181

[9]

Donnelly KL, 2005, J CLIN INVEST, V115, P1343, DOI 10.1172/JCI23621

[10] Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy [J].

Dutour, A. ;

Abdesselam, I. ;

Ancel, P. ;

Kober, F. ;

Mrad, G. ;

Darmon, P. ;

Ronsin, O. ;

Pradel, V. ;

Lesavre, N. ;

Martin, J. C. ;

Jacquier, A. ;

Lefur, Y. ;

Bernard, M. ;

Gaborit, B. .

DIABETES OBESITY & METABOLISM, 2016, 18 (09) :882-891

← 1 2 3 4 5 →